39 results
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
, global geopolitical tensions, supply chain disruptions, rising interest rates and rising inflation;
our business strategies and goals;
our plans … on favorable terms, or at all, particularly in light of recently worsening macroeconomic conditions, such as supply chain disruptions, rising interest
424B7
IMCR
Immunocore Holdings plc
5 Apr 24
Prospectus with selling stockholder info
4:34pm
and Israel, global geopolitical tensions, supply chain disruptions, rising interest rates and rising inflation;
our business strategies and goals … between Hamas and Israel, global geopolitical tensions, supply chain disruptions, rising interest rates and rising inflation;
our business strategies
S-3ASR
IMCR
Immunocore Holdings plc
20 Mar 24
Automatic shelf registration
8:51pm
between Hamas and Israel, global geopolitical tensions, supply chain disruptions, rising interest rates and rising inflation;
our business strategies … , such as the war in Ukraine and the state of war between Hamas and Israel, global geopolitical tensions, supply chain disruptions, rising interest
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
geopolitical tensions, supply chain disruptions, rising interest rates and rising inflation;
our business strategies and goals;
our plans to collaborate … macroeconomic factors, such as supply chain disruptions and rising inflation, may increase these expenses beyond what we currently anticipate. In recent months
6-K
EX-99.1
IMCR
Immunocore Holdings plc
7 Nov 23
Current report (foreign)
7:09am
fluctuations, and increases in commodity, energy and fuel prices as well as supply chain disruptions. The Board has concluded that while these may have
6-K
EX-99.2
z5jv26nbgx8dj5o
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.2
6j77xwgf
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.1
0i835p2ukh1a6v
10 Aug 23
Current report (foreign)
8:28am
6-K
928hgqaomk0 wlm3
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am
6-K
EX-99.1
rsmzsj0r1l ny33
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am
6-K
EX-99.1
jg2f26jlil7
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.2
qw0c2n 27rzwxt
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.1
vymfk
18 Apr 23
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
4:15pm
6-K
xk9zmnnebgyzy 638
18 Apr 23
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
4:15pm
6-K
EX-99.1
jjelrvd me3diz
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K
c7hew
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K
EX-99.1
gvb0 40al
2 Dec 22
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
5:08pm
6-K
4zwtktm5logtal3e
14 Nov 22
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
7:59am
6-K
EX-99.2
syempe92ul1l5c812
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.4
n5n omxd0drrx
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am